Dupilumab is the first biologic to significantly improve lung function in chronic obstructive pulmonary disease (COPD), according to topline results released Thursday.
A pivotal phase 3 trial of dupilumab (Dupixent) in adults with chronic obstructive pulmonary disease (COPD) showed that the biologic cut exacerbations by 30%, compared with placebo.
The topline results were announced in a release by Sanofi and Regeneron, which said more complete results will be presented in an upcoming scientific meeting.
All of the participants were current or former smokers; smoking accounts for 8 out of 10 COPD deaths in the United States, according to the CDC.
Besides meeting all key endpoints, the biologic also met all 12 secondary endpoints in the BOREAS trial, the first trial of 2 phase 3 studies to post results. In the randomized, double-blind, placebo-controlled, parallel-group, 52-week study, 939 adults aged 40 to 80 years received dupilumab (n = 468) or placebo (n = 471), added to standard-of-care inhaled therapy.
Results showed that patients on the biologic, which blocks the signaling of the interleukin (IL)-4 and IL-13 pathways, had improved patient-reported health-related quality of life as measured by St. George’s Respiratory Questionaire as well as reduction in the severity of respiratory symptoms of COPD.
Moderate or severe acute COPD exacerbations were slashed by 30% reduction over 52 weeks (P = .0005), the primary endpoint.
Lung function improved from baseline by 160 mL at 12 weeks compared with 77 mL for placebo (P < .0001), with the benefit versus placebo sustained through week 52 (P = .0003), both of which were key secondary endpoints.
Safety results were generally consistent with the known safety profile of dupilumab, which is already approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis and eosinophilic esophagitis.
Overall rates of adverse events were 77% for dupilumab and 76% for placebo.
Respiratory conditions like asthma and COPD are among the most costly health conditions in the United States, with spending of $35.5 billion and $34.3 billion, respectively, in 2016, according to a recent study. Worldwide, COPD is the third-leading cause of death.
The second, replicate phase 3 trial (NOTUS) is ongoing with data expected next year, said Sanofi and Regeneron.
“COPD is an urgent global health concern and a notoriously difficult-to-treat disease due to its heterogeneity, with no novel treatments approved in more than a decade,” said George D. Yancopoulos, MD, PhD, president and chief scientific officer at Regeneron. “These results also validate the role type 2 inflammation plays in driving COPD in these patients, advancing the scientific community’s understanding of the underlying biology of this disease.”
Reference
Dupixent demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial. Paris and Tarrytown, New York. Sanofi. March 23, 2023. https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-23-06-00-00-2632822. Accessed March 23, 2023
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More